- Opko Health Inc signed a deal with Merck & Co Inc potentially worth up to $922.5 million for its experimental Epstein-Barr virus vaccine.
- Shares of Opko rose as much as 24%, before paring gains to trade 9.4% higher at $1.16.
Opko Health shares rise on Merck deal for experimental Epstein-Barr vaccine
Opko Health Inc said on Wednesday it signed a deal with Merck & Co Inc potentially worth up to $922.5 million for its experimental Epstein-Barr virus vaccine.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/IJTUBDH5VNNRZBWCMTBLLWVXCM.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/CV5LYNOG7RLZ5BEOH5PDRHAJ74.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/RCWZE2OK3BNCJNRVFOS74NYF7M.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/6W5WJY7T4NLKVFJO5JX37LPYS4.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/BYL7ESQPMFMSNNVJSVCYKYTPH4.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/OGBROYPEZVMVNLCKMBDIE2XJCE.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/JG3AL7UAGVPBJHJUNQS4YZL4SE.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/IJTUBDH5VNNRZBWCMTBLLWVXCM.jpg&description=Opko%20Health%20shares%20rise%20on%20Merck%20deal%20for%20experimental%20Epstein-Barr%20vaccine){kind=link}